SYTE.bio

We develop linear DNA based precision therapeutics as Vaccines for Infectious Diseases and Cancer and Gene Therapies for genetic disorders

Global (world)

We are a pre-clinical stage company that develops DNA based therapeutics for several diseases. We have develped SARS-CoV-2 and Dengue DNA based vaccine candidates with promising in-vitro and in-vivo proof of concept results. As well we have also developed a novel approach to Melanoma Treatment with great in-vivo canine and feline case reports.

We do not use viral systems for gene delivery. We only use DNA + Liposomes for gene delivery and therapeutic effects for Infectious Diseases such as Dengue Virus and Cancer such as melanoma that are neglected diseases with no preventive or treatment therapeutics

We develop linear DNA based therapeutics for Infectious diseases such as COVID-19 and Dengue and for Oncology, specifically for Melanoma and Squamous Cell Carinoma. We have performed several proof of concept assays for our candidates with very promising results.

There are competitors that produce DNA based therapeutics as INOVIO but the main difference is that they use plasmidic circular DNA and we use linear DNA devoided of bacterial genetic elements

We differenciate from our competitors because we use non viral genetic sequences for vaccine and gene therapy development.
As well these types of molecules are produced in bacteria at lower prices than viral systems and are more efficient as well

We have won several competitions and prices:

2018 - ALL-TEC Competition - Argentina Biotechnology Innovation Award US$ 13.000 Funded

2019 - YPFtec - Argentina Science Ministry Biotechnology Innovation Award

2020 - Argenitna Science Ministry and Spain Fomento San Sebastian
Biotechnology Innovation Award US$ 3.000 Funded

Yes

We are currently filling the patent paperwork

The money will be spent on FDA guided pre-clinical trials, patenting, salaries and Phase I small clinical trial

We are open for discussing an offer for the investor